Literature DB >> 8356344

Coronary artery lesions and human immunodeficiency virus infection.

P Paton1, A Tabib, R Loire, R Tete.   

Abstract

The postmortem anatomopathological examination of eight heart-and-lung specimens obtained from eight HIV-seropositive patients was performed. Three patients were CDC stage II and five patients were CDC stage IV. The mean age was 27 (range: 23-32). Distal and proximal vascular lesions of the coronary arteries were observed. These impairments were marked by major excentric atherosclerosis (with 80-90% obstruction of the arterial lumen) or by fibrosis two-fold or six-fold the thickness of the tunica media. Sclero-hyalinosis of the smaller arteries and myocardial interstitial fibrosis lesions was also revealed. In view of the severity of the described lesions, the absence of any associated cardiovascular risk factors and the context of immunodepression, the role of a virus in the genesis of these lesions is suggested, in particular a virus of the herpes group.

Entities:  

Mesh:

Year:  1993        PMID: 8356344     DOI: 10.1016/s0923-2516(06)80033-6

Source DB:  PubMed          Journal:  Res Virol        ISSN: 0923-2516


  27 in total

Review 1.  Microorganisms in the aetiology of atherosclerosis.

Authors:  S A Morré; W Stooker; W K Lagrand; A J van den Brule; H W Niessen
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

2.  Risk stratification and prognosis of human immunodeficiency virus-infected patients with known or suspected coronary artery disease referred for stress echocardiography.

Authors:  Omar Wever Pinzon; Jorge Silva Enciso; Jorge Romero; Harikrishna Makani; Jose Fefer; Vani Gandhi; Sripal Bangalore; Farooq A Chaudhry
Journal:  Circ Cardiovasc Imaging       Date:  2011-07-12       Impact factor: 7.792

3.  Autonomic and cardiovascular function in HIV spectrum disease: early indications of cardiac pathophysiology.

Authors:  K A Brownley; J R Milanovich; S J Motivala; N Schneiderman; L Fillion; J A Graves; N G Klimas; M A Fletcher; B E Hurwitz
Journal:  Clin Auton Res       Date:  2001-10       Impact factor: 4.435

Review 4.  Hypertension in the HIV-infected patient.

Authors:  S Aoun; E Ramos
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 5.  Current update on HIV-associated vascular disease and endothelial dysfunction.

Authors:  Hong Mu; Hong Chai; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

6.  Endothelial function in HIV-infected persons.

Authors:  Anthony Solages; Joseph A Vita; David J Thornton; Jessica Murray; Timothy Heeren; Donald E Craven; C Robert Horsburgh
Journal:  Clin Infect Dis       Date:  2006-03-31       Impact factor: 9.079

7.  The association between alcohol consumption and prevalent cardiovascular diseases among HIV-infected and HIV-uninfected men.

Authors:  Matthew S Freiberg; Kathleen A McGinnis; Kevin Kraemer; Jeffrey H Samet; Joseph Conigliaro; R Curtis Ellison; Kendall Bryant; Lewis H Kuller; Amy C Justice
Journal:  J Acquir Immune Defic Syndr       Date:  2010-02       Impact factor: 3.731

8.  Coronary artery disease in HIV infected patients.

Authors:  Lelia Escaut; Jean Jacques Monsuez; Gilles Chironi; Mansouriah Merad; Elina Teicher; Denis Smadja; Alain Simon; Daniel Vittecoq
Journal:  Intensive Care Med       Date:  2003-05-09       Impact factor: 17.440

9.  Interleukin-18 predicts atherosclerosis progression in SIV-infected and uninfected rhesus monkeys (Macaca mulatta) on a high-fat/high-cholesterol diet.

Authors:  Jennifer H Yearley; Dongling Xia; Christine B Pearson; Angela Carville; Richard P Shannon; Keith G Mansfield
Journal:  Lab Invest       Date:  2009-04-20       Impact factor: 5.662

10.  Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis.

Authors:  Susan L Rosenkranz; Kevin E Yarasheski; Michael F Para; Richard C Reichman; Gene D Morse
Journal:  Metab Syndr Relat Disord       Date:  2007-06       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.